



NeoPharm Starts Enrolling Pancreatic Cancer Patients in Phase II Trial of LE-DT

LAKE BLUFF, Ill., Apr 20, 2010 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has started enrolling patients in its Phase II clinical trial for liposome entrapped docetaxel (LE-DT), as a frontline treatment of pancreatic cancer patients with locally advanced or metastatic disease. LE-DT is a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere^(R).

"Unfortunately, pancreatic cancer is one of the cancers which has no effective treatment. We are hoping that this new modality of treatment with LE-DT will bring some hope and treatment options to those unfortunate patients" commented Dr. Aquilur Rahman, President and Chief Executive Officer of NeoPharm.

"Following the very impressive results of the LE-DT Phase I trial, this open-label, Phase II study will help us determine the antitumor effect of LE-DT in this lethal disease. Progression Free Survival and Overall Survival along with a number of biologic markers such as CA-19-9 and SPARC expression, which are potentially related to the response of the disease, will be monitored. In addition, we will be evaluating the quality of life in these patients with metastatic disease."

Patients enrolled in the study will receive 110mg/m² of LE-DT administered intravenously over 60 minutes every three weeks. NeoPharm anticipates enrolling a total of 40 patients in this initial Phase II trial at three-to-four cancer centers in the US.

About NeoPharm, Inc.

NeoPharm, Inc., based in Lake Bluff, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer and other drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NeoPharm's Web site at www.NeoPharm.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "projects," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development programs, the initiation, progress, and outcomes of clinical trials of the Company's drug product candidates including, but not limited to LE-DT, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to difficulties or delays that may arise in the development, testing, regulatory approval, production, and marketing of the Company's drug and non-drug compounds, including, but not limited to, LE-DT, the Company's possible need to reduce its funding of certain of its development projects in order to conserve its cash resources, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug product candidates, including, but not limited to, LE-DT, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to commercialize any of its drug product candidates, including, but not limited to, LE-DT, and other risks of the type previously detailed from time to time in filings the Company formerly made with the Securities and Exchange Commission ("SEC"). Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. At the Company's request, the Company's obligation to file reports with the SEC was suspended effective February 12, 2009. For the foregoing reasons, you should not rely on these forward-looking statements or our previously filed SEC reports as a prediction of actual future results.

SOURCE: NeoPharm, Inc.

NeoPharm, Inc.
Martin K. McCarthy
847-887-0800

Copyright Business Wire 2010